Certara, Inc. (CERT) Stock Analysis

Certara’s primary competitive advantage lies in its entrenched position as the industry standard for biosimulation software in drug development. Over 90% of novel drugs approved by the FDA in recent years have relied on submissions using Certara’s platforms, notably Simcyp and Phoenix. This regulatory acceptance creates a formidable barrier to entry: both the FDA and other global agencies (20 in total) license and use Certara’s software, making it the “common language” for regulatory filings. Competitors such as Simulations Plus, Schrödinger, and NONMEM (ICON) offer capable products, but lack comparable regulatory validation and market penetration.

Switching costs are exceptionally high. Certara’s software is deeply embedded in client workflows, with scientists and regulatory teams trained specifically on its tools. Migrating to alternatives would require retraining staff and reformatting legacy data, risking operational disruption and regulatory uncertainty. This is reflected in Certara’s net retention rates, which consistently exceed 105%, above typical SaaS benchmarks.

The company’s proprietary scientific models and simulation algorithms, refined over decades, represent a unique intellectual asset that is difficult to replicate. Its services arm benefits from integration with its software, offering a level of regulatory confidence that standalone CROs cannot match. While the services segment faces more direct competition, the software division’s combination of regulatory trust, high switching costs, and network effects underpin Certara’s durable moat.